Filing Details
- Accession Number:
- 0000899243-22-013305
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-04-04 16:05:30
- Reporting Period:
- 2022-03-31
- Accepted Time:
- 2022-04-04 16:05:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1215126 | G Margaret Mcglynn | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-03-31 | 5,000 | $127.54 | 6,099 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-03-31 | 1,019 | $261.28 | 5,080 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-03-31 | 2,970 | $262.37 | 2,110 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-03-31 | 1,011 | $262.97 | 1,099 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Common Stock (right to buy) | Disposition | 2022-03-31 | 5,000 | $127.54 | 5,000 | $127.54 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 10,000 | 2025-05-31 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $261.28 (range $260.78 to $261.73).
- Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $262.37 (range $261.79 to $262.78).
- Open market sales reported on this line occurred at a weighted average price of $262.97 (range $262.80 to $263.34).
- Fully vested
Billionaire Hedge Funds
